Trial Profile

A clinical study of BMN 255 for the treatment of a subset of chronic renal disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMN 255 (Primary)
Indications Hyperoxaluria; Renal failure
Focus Adverse reactions; First in man
Sponsors BioMarin Pharmaceutical

Most Recent Events

27 Feb 2023 According to a BioMarin Pharmaceutical media release, the company concluded the multi-ascending dose phase of this study.
03 Aug 2022 According to a BioMarin Pharmaceutical media release, the company was recently given permission by the FDA to move forward with the multiple ascending dose portion of the study.
27 Apr 2022 According to a BioMarin Pharmaceutical media release, the company has completed the single ascending dose arm of this first-in-human study and is analyzing the results.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com